Literature DB >> 3693426

Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain.

H Nakagawa1, D R Groothuis, E S Owens, J D Fenstermacher, C S Patlak, R G Blasberg.   

Abstract

A total of 72 RG-2 transplanted gliomas were studied in 58 rats at three time points (1, 30, 240 min) after intravenous injection of [125I]radioiodinated serum albumin ([125I]RISA). The animals were divided into two groups: a control group that received no treatment and a second group that was treated with five doses of 1.5 mg/kg of dexamethasone over 2.5 days. Local tissue concentrations of [125I]RISA were measured with quantitative autoradiography based on morphological features of the tumors and used to calculate the tissue distribution space. Two models were used to analyze the data. A two compartment model yielded estimates of local blood-to-tissue influx constants (K1), lower limit extracellular volumes (Ve), and plasma vascular volumes (Vp) in different tumor regions. Treatment with dexamethasone consistently reduced the RISA distribution space in the RG-2 tumors; the reduction in Ve was statistically significant in almost all tumor regions: whole tumor Ve (mean +/- SE) was reduced from 0.14 +/- 0.02 ml g-1 in control animals to 0.08 +/- 0.01 ml g-1 in dexamethasone treated animals. K1 and Vp were also decreased in all tumor regions after treatment with dexamethasone (whole tumor K1 decreased from 2.36 +/- 0.89 to 0.83 +/- 0.29 microliter g-1 min-1 and Vp decreased slightly from 0.016 +/- 0.013 to 0.010 +/- 0.005 ml g-1 after dexamethasone treatment), but these changes were not statistically significant. A comparison of the tumor influx constants in control animals and the aqueous diffusion constants of two different size molecules (RISA and aminoisobutyric acid) suggests that the "pores" across RG-2 capillaries are large and may not restrict the free diffusion of RISA (estimated minimum pore diameter greater than 36 nm) and that the total pore area is approximately 6.2 X 10(-5) cm2 g-1 in RG-2 tumor tissue. The second model, which allows for diffusion and solvent drag of RISA across tumor capillaries and through the tissue, was used to analyze the distribution profiles of RISA in peripheral tumor and adjacent brain. This analysis was consistent with a small bulk flow of plasma-derived edema fluid (capillary filtration rate approximately equal to 0.8 microliter g-1 min-1) and a larger component of free diffusion of RISA (K approximately equal to 2 microliter g-1 min-1) through pores in the tumor vessels of control animals. Dexamethasone treatment markedly reduced or eliminated the filtration of plasma-derived fluid across tumor capillaries and the movement of RISA through the extracellular space by solvent drag.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3693426     DOI: 10.1038/jcbfm.1987.123

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  25 in total

1.  Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study.

Authors:  P F Behrens; H Langemann; R Strohschein; J Draeger; J Hennig
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  The concordance of MRI and quantitative autoradiography estimates of the transvascular transfer rate constant of albumin in a rat brain tumor model.

Authors:  Ramesh Paudyal; James R Ewing; Tavarekere N Nagaraja; Hassan Bagher-Ebadian; Robert A Knight; Swayamprava Panda; Mei Lu; Karyn Ledbetter; Joseph D Fenstermacher
Journal:  Magn Reson Med       Date:  2011-05-31       Impact factor: 4.668

3.  Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors.

Authors:  Yot Navalitloha; Erica S Schwartz; Elizabeth N Groothuis; Cathleen V Allen; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

4.  Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model.

Authors:  Moira C Ferrier; Hemant Sarin; Steve H Fung; Bawarjan Schatlo; Ryszard M Pluta; Sandeep N Gupta; Peter L Choyke; Edward H Oldfield; David Thomasson; John A Butman
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

5.  Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma.

Authors:  W R Shapiro; E M Hiesiger; G A Cooney; G A Basler; L E Lipschutz; J B Posner
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

6.  In vivo CT measurement of blood-brain transfer constant of iopamidol in human brain tumors.

Authors:  W T Yeung; T Y Lee; R F Del Maestro; R Kozak; T Brown
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

7.  Brain tumor iron uptake measured with positron emission tomography and 52Fe-citrate.

Authors:  U Roelcke; K L Leenders; K von Ammon; E W Radü; P Vontobel; I Günther; M Psylla
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

8.  Neuropathological and neurophysiological effects of interstitial white matter autologous and non-autologous protein containing solutions: further evidence for a glioma derived permeability factor.

Authors:  I R Whittle; J W Ironside; I R Piper; J D Miller
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

9.  Measurement of rat brain tumor kinetics using an intravascular MR contrast agent and DCE-MRI nested model selection.

Authors:  Wilson B Chwang; Rajan Jain; Hassan Bagher-Ebadian; Siamak P Nejad-Davarani; A S M Iskander; Ashley VanSlooten; Lonni Schultz; Ali S Arbab; James R Ewing
Journal:  J Magn Reson Imaging       Date:  2014-01-13       Impact factor: 4.813

10.  The effects of dexamethasone on transcapillary transport in experimental brain tumors: II. Canine brain tumors.

Authors:  P C Warnke; P Molnar; G D Lapin; A Kuruvilla; D R Groothuis
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.